TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06834282: CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)

Sponsor: CERo Therapeutics Holdings, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$848,232

Rescue Site Savings

+$565,488

Unlock Full NCT06834282 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06834282 Rescue Dossier →